These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6224604)

  • 1. Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
    Camaggi CM; Strocchi E; Giovannini M; Angelelli B; Costanti B; Zebini E; Ferrari P; Pannuti F
    Cancer Chemother Pharmacol; 1983; 11(1):19-22. PubMed ID: 6224604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients.
    Pannuti F; Camaggi CM; Strocchi E; Giovannini M; Canova N; Murari G
    Cancer Chemother Pharmacol; 1982; 9(2):122-3. PubMed ID: 6216987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.
    Camaggi CM; Strocchi E; Costanti B; Beghelli P; Ferrari P; Pannuti F
    Cancer Chemother Pharmacol; 1985; 14(3):232-4. PubMed ID: 3158449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.
    Salimtschik M; Mouridsen HT; Loeber J; Johansson E
    Cancer Chemother Pharmacol; 1980; 4(4):267-9. PubMed ID: 7438329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.
    Tamassia V; Battaglia A; Ganzina F; Isetta AM; Sacchetti G; Cavalli F; Goldhirsch A; Brunner K; Bernardo G; Robustelli della Cuna G
    Cancer Chemother Pharmacol; 1982; 8(2):151-6. PubMed ID: 6213319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients.
    Pannuti F; Camaggi CM; Strocchi E; Giovannini M; Di Marco AR; Costanti B
    Cancer Treat Rep; 1982 Dec; 66(12):2043-9. PubMed ID: 7139647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
    Laatikainen T; Nieminen U; Adlercreutz H
    Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.
    Izuo M; Iino Y; Endo K
    Breast Cancer Res Treat; 1981; 1(2):125-30. PubMed ID: 6216931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MPA at high doses in advanced breast cancer: a statistical evaluation.
    Pannuti F; Camaggi CM; Strocchi E; Martoni A
    Chemioterapia; 1986 Jun; 5(3):159-63. PubMed ID: 2941172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
    Etienne MC; Milano G; René N; Benedetti MS; Efthymiopoulos C; Vo Van ML; Hurteloup P; Montcuquet P; Frenay M; Namer M
    J Pharm Sci; 1991 Dec; 80(12):1130-2. PubMed ID: 1839998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of high dose progestin treatment in advanced breast cancer.
    Mattsson W
    Breast Cancer Res Treat; 1983; 3(2):231-5. PubMed ID: 6225476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.
    Halpenny O; Bye A; Cranny A; Feely J; Daly PA
    Med Oncol Tumor Pharmacother; 1990; 7(4):241-7. PubMed ID: 2149401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medroxyprogesterone acetate plasma levels after a single oral administration of two drug formulations.
    Pannuti F; Strocchi E; Longhi A; Comparsi R; Camaggi CM
    Chemioterapia; 1986 Aug; 5(4):237-9. PubMed ID: 2945648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.
    Mangioni C; Franceschi S; La Vecchia C; D'Incalci M
    Gynecol Oncol; 1981 Dec; 12(3):314-8. PubMed ID: 6458544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.